Creative Commons source reading · Headache and migraine
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.
Stephen D Silberstein; Joshua M Cohen; Michael J Seminerio; Ronghua Yang; Sait Ashina; Zaza Katsarava
Originally published in The journal of headache and pain · 2020-09-21
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication overuse (MO). Methods In a 12-week, phase 3 trial, patients with CM were randomized to fremanezumab quarterly (675 mg/placebo/placebo), monthly (675 mg/225 mg/225 mg), or placebo. Post hoc analyses assessed the impact of fremanezumab in patients with and without MO (monthly use of acute headache medication ≥15 days, migraine-specific acute medication ≥10 days, or combination medication ≥10 days) on efficacy outcomes, including headache days of at least moderate severity (HDs), and six-item Headache Impact Test (HIT-6) and Migraine-Specific Quality of Life (MSQoL) questionnaire scores. Results Of 1130 patients enrolled, 587 (51.9%) had baseline MO. Fremanezumab reduced placebo-adjusted least-squares mean (95% confidence interval) monthly HDs (- 2.2 [- 3.1 to - 1.2] and - 2.7 [- 3.7 to - 1.8]; P Conclusions Fremanezumab is effective for prevention of migraine in patients with CM, regardless of MO, and demonstrated a benefit over placebo in reducing MO.
Discussion
These post hoc analyses demonstrated that fremanezumab, compared with placebo, significantly reduced the monthly average number of headache days of at least moderate severity and led to a significantly greater proportion of patients who had a clinically meaningful ≥ 50% response rate, independently of the presence of MO in patients with CM. Similar reductions were also seen for migraine days. In patients with baseline MO, significantly more fremanezumab-treated patients reverted to no MO during the 12-week treatment period compared with those who received placebo.
Conclusion
Results from these post hoc analyses demonstrated that fremanezumab was efficacious in the preventive treatment of patients with CM regardless of the presence of MO and increased the likelihood of reversion from medication overuse to no medication overuse.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
